1. Leslie, PL, Ke, H, Zhang, Y. The MDM2 RING domain and central acidic domain play distinct roles in MDM2 protein homodimerization and MDM2-MDMX protein heterodimerization. J Biol Chem 2015; 290: 12941–12950.
Google Scholar | Crossref | Medline2. Wade, M, Wang, YV, Wahl, GM. The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol 2010; 20: 299–309.
Google Scholar | Crossref | Medline | ISI3. Wade, M, Li, YC, Wahl, GM. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer 2013; 13: 83–96.
Google Scholar | Crossref | Medline | ISI4. Valentin-Vega, YA, Barboza, JA, Chau, GP, El-Naggar, AK, Lozano, G. High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas. Hum Pathol 2007; 38: 1553–1562.
Google Scholar | Crossref | Medline5. Jin, X, Zhao, W, Zheng, M, Zhou, P, Niu, T. The role of MDM4 SNP34091 A>C polymorphism in cancer: a meta-analysis on 19,328 patients and 51,058 controls. Int J Biol Markers 2017; 32: e62–e67.
Google Scholar | SAGE Journals | ISI6. Xu, C, Zhu, J, Fu, W, et al. MDM4 Rs4245739 A > C polymorphism correlates with reduced overall cancer risk in a meta-analysis of 69477 subjects. Oncotarget 2016; 7: 71718–71726.
Google Scholar | Crossref | Medline7. Zhai, Y, Dai, Z, He, H, et al. A PRISMA-compliant meta-analysis of MDM4 genetic variants and cancer susceptibility. Oncotarget 2016; 7: 73935–73944.
Google Scholar | Crossref | Medline8. Wang, MJ, Luo, YJ, Shi, ZY, et al. The associations between MDM4 gene polymorphisms and cancer risk. Oncotarget 2016; 7: 55611–55623.
Google Scholar | Crossref | Medline9. Hashemi, M, Sanaei, S, Hashemi, SM, Eskandari, E, Bahari, G. Association of single nucleotide polymorphisms of the MDM4 gene With the susceptibility to breast cancer in a Southeast Iranian population sample. Clin Breast Cancer 2018; 18: e883–e891.
Google Scholar | Crossref | Medline10. Zhao, DM, Diao, YE, Xu, Q. Association of MDM4 gene rs4245739 polymorphism with the risk and clinical characteristics of colorectal cancer in a Chinese Han population. Pharmgenomics Pers Med 2020; 13: 673–678.
Google Scholar | Medline11. Mohammad Khanlou, Z, Pouladi, N, Hosseinpour Feizi, M, Pedram, N. Lack of associations of the MDM4 rs4245739 polymorphism with risk of thyroid cancer among Iranian-Azeri patients: a case-control study. Asian Pac J Cancer Prev 2017; 18: 1133–1138.
Google Scholar | Medline12. Yu, H, Wang, LE, Liu, Z, et al. Polymorphisms of MDM4 and risk of squamous cell carcinoma of the head and neck. Pharmacogenet Genomics 2011; 21: 388–396.
Google Scholar | Crossref | Medline13. Zhang, YW, Guan, J, Zhang, Y, Qiu, YR, Chen, LH. Role of an MDM4 polymorphism in the early age of onset of nasopharyngeal carcinoma. Oncol Lett 2012; 3: 1115–1118.
Google Scholar | Crossref | Medline14. Thunell, LK, Bivik, C, Waster, P, et al. MDM2 SNP309 promoter polymorphism confers risk for hereditary melanoma. Melanoma Res 2014; 24: 190–197.
Google Scholar | Crossref | Medline15. Wang, MY, Jia, M, He, J, et al. MDM4 Genetic variants and risk of gastric cancer in an eastern Chinese population. Oncotarget 2017; 8: 19547–19555.
Google Scholar | Crossref | Medline16. Yu, F, Jiang, Z, Song, A. Association of rs11801299 and rs1380576 polymorphisms at MDM4 with risk, clinicopathological features and prognosis in patients with retinoblastoma. Cancer Epidemiol 2019; 58: 153–159.
Google Scholar | Crossref | Medline17. Liu, J, Tang, X, Li, M, et al. Functional MDM4 rs4245739 genetic variant, alone and in combination with P53 Arg72Pro polymorphism, contributes to breast cancer susceptibility. Breast Cancer Res Treat 2013; 140: 151–157.
Google Scholar | Crossref | Medline18. Zhou, L, Zhang, X, Li, Z, et al. Association of a genetic variation in a miR-191 binding site in MDM4 with risk of esophageal squamous cell carcinoma. PLOS One 2013; 8: e64331.
Google Scholar | Crossref | Medline19. Fan, C, Wei, J, Yuan, C, et al. The functional TP53 rs1042522 and MDM4 rs4245739 genetic variants contribute to Non-Hodgkin lymphoma risk. PLOS One 2014; 9: e107047.
Google Scholar | Crossref | Medline20. Gao, F, Xiong, X, Pan, W, et al. A regulatory MDM4 genetic variant locating in the binding sequence of multiple MicroRNAs contributes to susceptibility of small cell lung cancer. PLOS One 2015; 10: e0135647.
Google Scholar | Crossref | Medline21. Gansmo, LB, Romundstad, P, Birkeland, E, et al. MDM4 SNP34091 (rs4245739) and its effect on breast-, colon-, lung-, and prostate cancer risk. Cancer Med 2015; 4: 1901–1907.
Google Scholar | Crossref | Medline22. Gansmo, LB, Bjornslett, M, Halle, MK, et al. The MDM4 SNP34091 (rs4245739) C-allele is associated with increased risk of ovarian-but not endometrial cancer. Tumour Biol 2016; 37: 10697–10702.
Google Scholar | Crossref | Medline23. Pedram, N, Pouladi, N, Feizi, MA, Montazeri, V, Sakhinia, E, Estiar, MA. Analysis of the association between MDM4 rs4245739 single nucleotide polymorphism and breast cancer susceptibility. Clin Lab 2016; 62: 1303–1308.
Google Scholar | Crossref | Medline24. Hu, Z, Wu, C, Shi, Y, et al. A genome-wide association study identifies two new lung cancer susceptibility loci at 13q12.12 and 22q12.2 in Han Chinese. Nat Genet 2011; 43: 792–796.
Google Scholar | Crossref | Medline25. Wang, Z, Sturgis, EM, Zhang, Y, et al. Combined p53-related genetic variants together with HPV infection increase oral cancer risk. Int J Cancer 2012; 131: E251–E258.
Google Scholar | Crossref | Medline | ISI26. Wu, GC, Zhang, ZT. Genetic association of single nucleotide polymorphisms in P53 pathway with gastric cancer risk in a Chinese Han population. Med Oncol 2015; 32.
Google Scholar | Crossref27. Yu, H, Sturgis, EM, Liu, Z, Wang, LE, Wei, Q, Li, G. Modifying effect of MDM4 variants on risk of HPV16-associated squamous cell carcinoma of oropharynx. Cancer 2012; 118: 1684–1692.
Google Scholar | Crossref | Medline28. Garcia-Closas, M, Couch, FJ, Lindstrom, S, et al. Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet 2013; 45: 392–398. 8e1–2.
Google Scholar | Crossref | Medline | ISI29. Wynendaele, J, Bohnke, A, Leucci, E, et al. An illegitimate microRNA target site within the 3′ UTR of MDM4 affects ovarian cancer progression and chemosensitivity. Cancer Res 2010; 70: 9641–9649.
Google Scholar | Crossref | Medline